TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Jan 10, 2024
|
|
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Jan 09, 2024
|
|
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Jan 05, 2024
|
|